Nitric oxide injection for solid tumors that can’t be removed
Part of Cancer clinical trials.
This Phase 1 study tests whether injecting nitric oxide into certain solid tumors is safe and may help shrink tumors that cannot be removed with surgery. It includes adults with measurable, treatment-resistant skin or under-skin (cutaneous or subcutaneous) tumors and checks for side effects and early signs of benefit.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and able to give informed consent
- Have a skin or under-skin solid tumor (or metastasis) that cannot be removed (unresectable), proven by pathology (biopsy)
- Have measurable tumor areas on scans and usually at least one target spot you can feel/see; the target should be at least 4.5 mm in length and depth
- Have tried standard cancer treatments (or there aren’t standard options) and your tumor hasn’t responded or has progressed
- Be healthy enough for treatment: blood counts and organ function are adequate, and you’ve not had radiation to the target area within the last 12 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug, N17350, that is injected directly into tumors. It is for people with advanced solid tumors that have stopped responding to standard treatments or who cannot receive them. The study aims to see if this approach is safe and effective.
This trial tests a combination of two injections, OH2 and BS006, for people with advanced solid tumors that have not responded to standard treatments. The injections are given directly into the tumor, aiming to shrink or control the cancer.
This Phase 1 trial tests NBL-020, an injected medicine, in adults with advanced solid cancers (and possibly some skin T-cell lymphoma) to see how it works and how safe it is. You may be considered if standard treatment has stopped working or isn’t tolerated and if you can provide recent tumor tissue for lab testing.
This Phase 1 study tests OH2 given as an injection directly into certain tumors (intratumoral injection) in people with advanced melanoma or several other solid cancers that are hard to remove. It aims to see whether the treatment is safe and if it can help control cancer by reaching the tumor more directly.
This early-phase study tests a medicine called SGN1 given directly into a solid tumor. It’s for people with advanced cancers that have not responded to standard treatment (or don’t have good standard options) and aims to see if the injection is safe and may work.
This trial tests a new treatment that combines two drugs—OVV-01 (injected directly into tumors) and AK112 (given by vein)—for advanced solid cancers that have not responded to standard treatments. The goal is to see if this combination can shrink tumors and help patients live longer.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.